Skip to main content
News Archive
  1. Home
  2. News
  3. News Archive
HNCIG-6/NRG HN002 RESULTS PUBLISHED IN JCO Read Article

HNCIG-6/NRG HN002 RESULTS PUBLISHED IN JCO

This randomized phase II trial for good-risk HPV-associated OPSCC compared reduced-dose radiation (60 Gy) with or without concurrent weekly cisplatin. The RT-only arm was accelerated at 6 fractions per week. The accelerated reduced-dose radiation alone arm failed to meet statistical conditions for PFS acceptability, whereas the CRT arm did, justifying its advancement as a study arm of NRG-HN005. Read more

Read Article
HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Read Article

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Members of the intergroup recently published an important guideline for defining postoperative RT volumes post-resection, aiming to promote harmonization of post-operative RT globally and to reduce treatment variation among clinicians. Read more

Read Article
ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY DURING THE COVID-19 PANDEMIC PUBLISHED IN RED JOURNAL Read Article

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY DURING THE COVID-19 PANDEMIC PUBLISHED IN RED JOURNAL

Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. Read more

Read Article
HNCIG PUBLISHES INTERNATIONAL CONSENSUS GUIDELINES FOR HEAD AND NECK SURGICAL ONCOLOGY PRACTICE IN TIMES OF SEVERE RESOURCE CONSTRAINT DURING COVID-19 CRISIS Read Article

HNCIG PUBLISHES INTERNATIONAL CONSENSUS GUIDELINES FOR HEAD AND NECK SURGICAL ONCOLOGY PRACTICE IN TIMES OF SEVERE RESOURCE CONSTRAINT DURING COVID-19 CRISIS

These guidelines represent 35 international professional societies and national clinical trial groups and were endorsed by 39 societies and professional bodies and sought to decrease inconsistency and uncertainty and to provide reassurance for clinicians. ​ Read more

Read Article
HNCIG-2/EORTC 1420 DESIGN AND RATIONALE PUBLISHED IN FRONTIERS Read Article

HNCIG-2/EORTC 1420 DESIGN AND RATIONALE PUBLISHED IN FRONTIERS

Dysphagia is one of the most serious and common adverse events after curative-intent treatment for HNSCC, with huge QOL impact. The EORTC 1420 "Best of" trial is an ongoing open-label phase III prospective randomized trial assessing the "best of" surgery compared to the "best of" RT initially in patients with T1-2N0 OPSCCs, SGSCC, and T1N0 hypopharyngeal SCC. The main objective is to compare patient-reported swallowing function over the first year after randomization between TORS and IMRT. Read more

Read Article
HNCIG-4/DE-ESCALATE RESULTS PUBLISHED IN LANCET Read Article

HNCIG-4/DE-ESCALATE RESULTS PUBLISHED IN LANCET

On this phase III trial, patients with low-risk oropharyngeal cancer were assigned to receive standard cisplatin-based CRT or radiotherapy plus cetuximab. Compared with the standard of care regimen, cetuximab showed no toxicity benefit, and negatively impacted tumor control. Read more

Read Article